|
|
 |
|
Viewing report
|
|
|
|
Antibody Drug Targets and Special Focus on Leukemias & Lymphomas
Bioseeker, Dec 2007, Pages: 430
In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. This extensive 430+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are currently more than 400 antibody based drugs in development for the treatment of cancer. We surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
Drug targets and their associated antibodies have been analyzed by us according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancer stem cells
- Conjugated antibodies
- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
- 31 Targeted cancer indications
- Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
- Antibody therapeutic companies
Gain insight into the current challenges and commercial opportunities associated with leukemia and Lymphoma therapy. Explore the strengths and weaknesses associated with compounds in clinical development and the scientific rationale for most novel therapeutics in leukemia and Lymphoma R&D.
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. In this report, we do not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics, but also provide one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. We present both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs.
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma (NHL). The lymphoma market is a complex topic and several pitfalls await actors not well prepared. The report will guide thru this field and bring structure and knowledge enable our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
Customers who bought this item also bought
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Novel Targets in Drug Discovery
Antibody Drug Targets and Special Focus on Leukemias & Lymphomas
Kinases: Advanced Strategies and Multiple Targets for Drug Discovery
Antibody Drug Target Atlas in Oncology
Transmembrane Transporters: High Sales, High Potential as Drug Targets
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Proteases as Drug Targets: Technologies and Opportunities for Drug Discovery
|
|
|
|
